GlobalData operates through a One Platform Model that integrates data analytics and non-healthcare insights, with the majority of revenue generated in the USA. The company has recently transitioned from AIM to the LSE main market, positioning itself for growth and greater institutional investor access.
Cyborg Score Rationale
GlobalData demonstrates solid fundamentals with strong analyst support (consensus Buy rating), a healthy net margin of 11.96%, and solid ROE of 12.99%. However, elevated P/E ratio (42.20) and modest market cap of £597M suggest growth expectations may be priced in, with mixed recent momentum.
Top Insights
Recent LSE main market admission (March 2026) signals expanded institutional credibility and potential capital raising capabilities
Strong analyst consensus with 4 Buy ratings and price target of GBX 195, suggesting 130% upside from March 2026 levels
Two-segment strategy (Healthcare Data Analytics + Non-Healthcare Insights) diversifies revenue while targeting high-margin, recurring subscription models
USA represents majority of revenue exposure, concentrating geographic growth opportunity but creating currency and geopolitical risks
Named Competitors
Market Intelligence Platform — Global business intelligence and events
Business Data Solutions — Commercial data and analytics
Consumer Research — Market research and consumer insights
Recent Developments
(January 2026) Announced transition to LSE main market from AIM
(March 2026) Completed admission to LSE main market
(March 2026) Posted quarterly earnings with net margin of 11.96% and ROE of 12.99%
Open the full interactive GlobalData PLC report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.